Research & Development July 7, 2026 Vertex signs agreement to acquire Crinetics for $10bn By Salong Debbarma Approved unanimously by both companies’ boards, the acquisition will see Vertex pay $85.00 per share in cash for all outstanding shares of Crinetics. It is expected to close
Research & Development July 7, 2026 EC approves AbbVie’s Tepkinly combination for follicular lymphoma By Salong Debbarma The decision is based on data from the pivotal Phase III EPCORE FL-1 trial, which assessed the efficacy and safety of the fixed-duration Tepkinly plus lenalidomide and rituximab
Research & Development July 6, 2026 Novartis to acquire Myricx Bio in up to $1.5bn deal By Salong Debbarma The deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments. It is expected to close in the second half of 2026, pending
Research & Development July 6, 2026 Besins Healthcare boosts drug delivery portfolio with UniD deal By Salong Debbarma UniD Manufacturing’s expertise includes advanced polymer systems used in complex delivery formats such as implants and vaginal rings. Besins Healthcare will acquire UniD’s site in Seraing, Belgium. A
Research & Development July 3, 2026 SK bioscience to lead Gates Foundation-funded ROTOR project By Salong Debbarma The project will involve collaboration with global health organisation PATH and consulting firm Slalom. The initiative seeks to create a platform that uses AI to analyse a wide
Research & Development July 3, 2026 European Commission approves Novartis’ Itvisma to treat SMA By Salong Debbarma With this decision, Itvisma becomes the only gene replacement therapy which is currently approved for this wider patient population within the EU. Itvisma works by providing a functional
Research & Development July 2, 2026 Insilico Medicine, Takeda partner on AI-driven drug discovery By Salong Debbarma Under the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria. Takeda will take the lead in advancing selected
OncologyResearch & Development July 2, 2026 Inocras, AimedBio team up for cancer treatments By Salong Debbarma The deal includes a strategic equity investment by AimedBio in Inocras and a joint research agreement between the two companies. Additionally, the whole genome sequencing (WGS) capabilities of
Research & DevelopmentApprovals July 1, 2026 US FDA rejects approval of Unicycive’s kidney disease therapy By Salong Debbarma This decision was issued in a Complete Response Letter (CRL) which cited deficiencies at a third-party manufacturing facility producing OLC. The FDA did not raise concerns related to
Research & DevelopmentRegulation July 1, 2026 Eli Lilly and Innovent agree Verzenios commercialisation deal in China By Salong Debbarma Under this agreement, Innovent will handle the marketing, distribution and promotion of the product within the region, while Eli Lilly will continue to manage manufacturing, supply and development. Verzenios